Merck and Pfizer Announce Discontinuation of Phase III JAVELIN...
DARMSTADT, Germany and NEW YORK, March 20, 2019, /PRNewswire-AsiaNet/-- Not intended for US, Canada and UK-based mediaMerck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chem...
Authors: LATEST ASIANET NEWS RELEASES